401 related articles for article (PubMed ID: 19671025)
1. Hexyl aminolevulinate fluorescence cystoscopy in bladder cancer.
Sievert KD; Kruck S
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1055-63. PubMed ID: 19671025
[TBL] [Abstract][Full Text] [Related]
2. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
[TBL] [Abstract][Full Text] [Related]
3. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer.
Witjes JA; Douglass J
Nat Clin Pract Urol; 2007 Oct; 4(10):542-9. PubMed ID: 17921969
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden.
Malmström PU; Hedelin H; Thomas YK; Thompson GJ; Durrant H; Furniss J
Scand J Urol Nephrol; 2009; 43(3):192-8. PubMed ID: 19330681
[TBL] [Abstract][Full Text] [Related]
5. Recent developments in fluorescence cystoscopy: do novel agents bring a benefit?
Schmidbauer J; Marberger M
Curr Opin Urol; 2007 Sep; 17(5):347-51. PubMed ID: 17762629
[TBL] [Abstract][Full Text] [Related]
6. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.
Malmström PU; Grabe M; Haug ES; Hellström P; Hermann GG; Mogensen K; Raitanen M; Wahlqvist R
Scand J Urol Nephrol; 2012 Apr; 46(2):108-16. PubMed ID: 22087730
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
[TBL] [Abstract][Full Text] [Related]
8. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.
Jocham D; Witjes F; Wagner S; Zeylemaker B; van Moorselaar J; Grimm MO; Muschter R; Popken G; König F; Knüchel R; Kurth KH
J Urol; 2005 Sep; 174(3):862-6; discussion 866. PubMed ID: 16093971
[TBL] [Abstract][Full Text] [Related]
9. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.
Grossman HB; Gomella L; Fradet Y; Morales A; Presti J; Ritenour C; Nseyo U; Droller MJ;
J Urol; 2007 Jul; 178(1):62-7. PubMed ID: 17499283
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence cystoscopy: is it ready for use in routine clinical practice?
Spiess PE; Grossman HB
Curr Opin Urol; 2006 Sep; 16(5):372-6. PubMed ID: 16905985
[TBL] [Abstract][Full Text] [Related]
11. [Fluorescence diagnosis and photodynamic therapy in urology].
Stepp H; Waidelich R
Aktuelle Urol; 2007 Nov; 38(6):455-64. PubMed ID: 17987533
[TBL] [Abstract][Full Text] [Related]
12. Hexyl aminolevulinate: 5-ALA hexylester, 5-ALA hexylesther, aminolevulinic acid hexyl ester, hexaminolevulinate, hexyl 5-aminolevulinate, P 1206.
Drugs R D; 2005; 6(4):235-8. PubMed ID: 15991884
[TBL] [Abstract][Full Text] [Related]
13. [The impact of ALA (5-aminolevulinic acid)-fluorescence detection on the prognosis of superficial bladder cancer].
Daniltchenko D; Riedl C; Koenig F; Daha LK; Sachs M; Schnorr D
Aktuelle Urol; 2004 Nov; 35(6):497-501. PubMed ID: 15526230
[TBL] [Abstract][Full Text] [Related]
14. Blue-sky thinking about blue-light cystoscopy.
Thomas K; O'Brien T
BJU Int; 2009 Oct; 104(7):887-9. PubMed ID: 19583718
[No Abstract] [Full Text] [Related]
15. Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305).
Mostafid H; Bunce C;
BJU Int; 2009 Oct; 104(7):889-90. PubMed ID: 19549121
[No Abstract] [Full Text] [Related]
16. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid.
Drăgoescu O; Tomescu P; Pănuş A; Enache M; Maria C; Stoica L; Pleşea IE
Rom J Morphol Embryol; 2011; 52(1):123-7. PubMed ID: 21424043
[TBL] [Abstract][Full Text] [Related]
18. The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer.
Bunce C; Ayres BE; Griffiths TR; Mostafid H; Kelly J; Persad R; Kockelbergh R
BJU Int; 2010 Feb; 105 Suppl 2():2-7. PubMed ID: 20089091
[No Abstract] [Full Text] [Related]
19. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?
Loidl W; Schmidbauer J; Susani M; Marberger M
Eur Urol; 2005 Mar; 47(3):323-6. PubMed ID: 15716195
[TBL] [Abstract][Full Text] [Related]
20. Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.
Yang LP
Mol Diagn Ther; 2014 Feb; 18(1):105-16. PubMed ID: 24248555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
